Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line ...

Researchers from Liverpool School of Tropical Medicine (LSTM) have completed a Phase I clinical trial for a new oral ...

YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, announced today that Communications Medicine, a Nature Portfolio journal, has published a peer-reviewed paper on the ...

Based on its cash, cash equivalents and investments as of December 31, the company continues to expect its cash runway to fund operations into ...

Pre-clinical studies have demonstrated the synergistic effects of GLP-1RA and icosabutate on hepatic fibrosis reduction. Rob de Ree, Chief Executive Officer of NorthSea Therapeutics, said ...

Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung ...

Plus Therapeutics (PSTV) announces the publication of results in a peer-reviewed manuscript titled, “Treatment of Recurrent Glioma by Rhenium ...

we believe that Callio Therapeutics will be the first company to show the clinical benefit of this exciting new multi-payload ADC approach and is well positioned to transform cancer therapy." ...

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") ...